MX2022002447A - Composiciones y métodos para el tratamiento de la infección por influenza a. - Google Patents
Composiciones y métodos para el tratamiento de la infección por influenza a.Info
- Publication number
- MX2022002447A MX2022002447A MX2022002447A MX2022002447A MX2022002447A MX 2022002447 A MX2022002447 A MX 2022002447A MX 2022002447 A MX2022002447 A MX 2022002447A MX 2022002447 A MX2022002447 A MX 2022002447A MX 2022002447 A MX2022002447 A MX 2022002447A
- Authority
- MX
- Mexico
- Prior art keywords
- influenza
- infection
- treatment
- methods
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893747P | 2019-08-29 | 2019-08-29 | |
| US202062993519P | 2020-03-23 | 2020-03-23 | |
| US202063040966P | 2020-06-18 | 2020-06-18 | |
| PCT/US2020/048635 WO2021041989A1 (en) | 2019-08-29 | 2020-08-28 | Compositions and methods for treatment of influenza a infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002447A true MX2022002447A (es) | 2022-08-08 |
Family
ID=72473986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002447A MX2022002447A (es) | 2019-08-29 | 2020-08-28 | Composiciones y métodos para el tratamiento de la infección por influenza a. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220306728A1 (enExample) |
| EP (1) | EP4021502A1 (enExample) |
| JP (2) | JP2022545553A (enExample) |
| KR (1) | KR20220061999A (enExample) |
| CN (1) | CN115052630A (enExample) |
| AU (1) | AU2020335922A1 (enExample) |
| BR (1) | BR112022003529A2 (enExample) |
| CA (1) | CA3148990A1 (enExample) |
| IL (1) | IL290752B2 (enExample) |
| MX (1) | MX2022002447A (enExample) |
| WO (1) | WO2021041989A1 (enExample) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
| HRP20150279T1 (hr) * | 2007-12-26 | 2015-05-08 | Xencor, Inc. | Fc inaäśice s promijenjenim vezanjem na fcrn |
| PL2350128T3 (pl) | 2008-10-22 | 2015-03-31 | Inst Res Biomedicine | Sposoby wytwarzania przeciwciał z komórek plazmatycznych |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| MX2017009759A (es) * | 2015-01-28 | 2017-10-27 | Pfizer | Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable. |
| SG11201805001UA (en) * | 2016-01-13 | 2018-07-30 | Medimmune Llc | Method of treating influenza a |
| US12304928B2 (en) * | 2018-05-18 | 2025-05-20 | Cz Biohub Sf, Llc | Epitope restriction for antibody selection |
| WO2020221450A1 (en) * | 2019-04-30 | 2020-11-05 | Humabs Biomed Sa | Antibodies and methods for treatment of influenza a infection |
-
2020
- 2020-08-27 IL IL290752A patent/IL290752B2/en unknown
- 2020-08-28 MX MX2022002447A patent/MX2022002447A/es unknown
- 2020-08-28 AU AU2020335922A patent/AU2020335922A1/en active Pending
- 2020-08-28 CA CA3148990A patent/CA3148990A1/en active Pending
- 2020-08-28 US US17/638,630 patent/US20220306728A1/en active Pending
- 2020-08-28 KR KR1020227010317A patent/KR20220061999A/ko active Pending
- 2020-08-28 CN CN202080076781.6A patent/CN115052630A/zh active Pending
- 2020-08-28 WO PCT/US2020/048635 patent/WO2021041989A1/en not_active Ceased
- 2020-08-28 EP EP20771696.0A patent/EP4021502A1/en active Pending
- 2020-08-28 BR BR112022003529A patent/BR112022003529A2/pt unknown
- 2020-08-28 JP JP2022513477A patent/JP2022545553A/ja active Pending
-
2025
- 2025-05-20 JP JP2025084157A patent/JP2025124708A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL290752B2 (en) | 2026-02-01 |
| JP2022545553A (ja) | 2022-10-27 |
| US20220306728A1 (en) | 2022-09-29 |
| WO2021041989A1 (en) | 2021-03-04 |
| AU2020335922A1 (en) | 2022-03-24 |
| CN115052630A (zh) | 2022-09-13 |
| IL290752B1 (en) | 2025-10-01 |
| IL290752A (en) | 2022-04-01 |
| JP2025124708A (ja) | 2025-08-26 |
| EP4021502A1 (en) | 2022-07-06 |
| WO2021041989A9 (en) | 2021-05-14 |
| CA3148990A1 (en) | 2021-03-04 |
| BR112022003529A2 (pt) | 2022-05-24 |
| KR20220061999A (ko) | 2022-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20257731B (en) | Substituted aminothiazoles as dgkzeta inhibitors for immune activation | |
| CR20220545A (es) | ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2) | |
| MX2019001814A (es) | Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart. | |
| MX2019002978A (es) | Composiciones que comprenden una bacteria no patogena y metodos para proteger plantas y animales anfitriones contra enfermedades micoticas, bacterianas y virales. | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| MX2025002439A (es) | Compuestos ciclicos de urea tiazolilo para el tratamiento del hsv | |
| MX2022002946A (es) | Inhibidores de cdk y su uso como productos farmaceuticos. | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| ZA202300259B (en) | Compound for the treatment of coronaviral infections | |
| EP4445913A3 (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
| ZA202000680B (en) | Obinutuzumab treatment of a dlbcl patient subgroup | |
| WO2021046315A3 (en) | Inhibitors of encephalitic alphaviruses | |
| PH12022550843A1 (en) | Thienopyrimidones as trpa1 inhibitors | |
| MX2022000811A (es) | Inhibidores de enzimas. | |
| PH12022550846A1 (en) | Thienopyrimidones as trpa1 inhibitors | |
| EA202091563A1 (ru) | Человеческие антитела к гемагглютинину вируса гриппа | |
| ZA202210032B (en) | Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19 | |
| WO2022173714A3 (en) | Antibodies that bind metapneumovirus, antigenic metapneumovirus proteins, and uses thereof | |
| MX2024006374A (es) | Composiciones y metodos de bioproteccion basados en microalgas para plantas hospederas. | |
| PH12015502128A1 (en) | Novel dosing regimens of celgosivir for the treatment of dengue | |
| WO2022109317A9 (en) | Anti-influenza antibodies and combinations thereof | |
| ZA202211253B (en) | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases | |
| PL428045A1 (pl) | Szczepionka do profilaktyki i leczenia zakażeń C. difficile oraz jej zastosowanie | |
| MX2022002447A (es) | Composiciones y métodos para el tratamiento de la infección por influenza a. | |
| WO2019209952A3 (en) | Vip antagonists and uses in treating cancer |